Aura Biosciences, Inc. (AURA) Form 8-K — Jul 8, 2026
Aura Biosciences appointed Jeremy Bender, Ph.D., M.B.A., to its Board of Directors, increasing the board size from six to seven members. Dr. Bender, the former CEO of Day One Biopharmaceuticals which was acquired for $2.5 billion, brings extensive experience in late-stage development and commercialization in rare oncology. Dr.
Key figures
- Board Retainer Usd
- 40000
- Annual Award Cap Usd
- 400000
- Initial Award Cap Usd
- 800000
- Initial RSUAward Shares
- 30000
- Initial Option Award Shares
- 60000
Price after filing
1 day: -3.4%7 days: -3.3%30 days: +6.5%
Close on the filing date to close N calendar days later (from $7.25). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.